NBTY Announces Agreement to Purchase Leiner Healt...(operations efficiently; (xvii) consumer ...),Health

Date:6/10/2008

operations efficiently; (xvii) consumer acceptance of NBTY's products; (xviii) the inability of NBTY to renew leases for its retail locations; (xix) the inability of NBTY's retail stores to attain or maintain profitability; (xx) the absence of clinical trials for many of NBTY's products; (xxi) sales and earnings volatility and/or trends for the Company and its market segments; (xxii) the efficacy of NBTY's Internet and on-line sales and marketing strategies; (xxiii) fluctuations in foreign currencies, including the British pound, the Euro and the Canadian dollar; (xxiv) import-export controls on sales to foreign countries; (xxv) the inability of NBTY to secure favorable new sites for, and delays in opening, new retail and manufacturing locations; (xxvi) introduction of and compliance with new federal, state, local or foreign legislation or regulation or adverse determinations by regulators anywhere in the world (including the banning of products) and more particularly Good Manufacturing Practices in the United States, the Food Supplements Directive and Traditional Herbal Medicinal Products Directive in Europe and Section 404 requirements of the Sarbanes-Oxley Act of 2002; (xxvii) the mix of NBTY's products and the profit margins thereon; (xxviii) the availability and pricing of raw materials; (xxix) risk factors discussed in NBTY's filings with the U.S. Securities and Exchange Commission; (xxx) adverse effects on NBTY as a result of increased energy prices and potentially reduced traffic flow to NBTY's retail locations; (xxxi) adverse tax determinations; (xxxii) the loss of a significant customer of the Company; (xxxiii) potential investment losses as a result of liquidity conditions; and (xxxiv) other factors beyond the Company's control.

Readers are cautioned not to place undue reliance on forward-looking statements. NBTY cannot guarantee future results, trends, events, levels of activity, performance or achievements. NBTY does not undertake and specificall
'/>"/>

SOURCE NBTY, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine news :

1. CorVel Announces Record Earnings
2. SUA Insurance Company Announces Partnership With American Safety Indemnity Company
3. WellPoint Announces Appearance at Upcoming Conference
4. MINRAD International, Inc. Announces FDA Approval of Petrem(TM) Sevoflurane
5. Synthetech Announces Appointment of Dr. Gregory R. Hahn as President and Chief Executive Officer
6. Mylan Announces Final FDA Approval for Zaleplon Capsules
7. PharMEDium Announces National Rollout of Electronic 222 Ordering Initiative
8. Senetek PLC Announces Key Personnel Appointments
9. QLT announces agreement to sell Aczone(R) to Allergan for approximately US$150 million
10. Health Robotics Announces IV Station (TM Pending) a Centrally-Controlled,
11. Universal Health Realty Income Trust Announces Dividend Increase